| Schedule of segment net loss and significant segment expenses |
The following table presents the segment net loss and significant segment expenses for the three and six months ended June 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
|
2026 |
|
|
2025 |
|
Employee-related expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development employee-related expenses |
|
$ |
4,050 |
|
|
$ |
3,159 |
|
|
|
$ |
8,169 |
|
|
$ |
6,323 |
|
General and administrative employee-related expenses |
|
|
1,592 |
|
|
|
1,518 |
|
|
|
|
3,347 |
|
|
|
2,855 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and preclinical expenses |
|
|
1,905 |
|
|
|
1,737 |
|
|
|
|
3,483 |
|
|
|
3,738 |
|
Clinical and development expenses |
|
|
8,461 |
|
|
|
5,692 |
|
|
|
|
18,125 |
|
|
|
10,096 |
|
Chemistry, manufacturing, and control expenses |
|
|
1,003 |
|
|
|
3,847 |
|
|
|
|
4,521 |
|
|
|
5,331 |
|
Non-clinical science expenses |
|
|
596 |
|
|
|
1,197 |
|
|
|
|
910 |
|
|
|
1,903 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-employee-related general and administrative expenses |
|
|
2,314 |
|
|
|
2,185 |
|
|
|
|
5,136 |
|
|
|
4,914 |
|
Other segment expenses1 |
|
|
2,364 |
|
|
|
649 |
|
|
|
|
3,835 |
|
|
|
730 |
|
Net loss |
|
$ |
22,285 |
|
|
$ |
19,984 |
|
|
|
$ |
47,526 |
|
|
$ |
35,890 |
|
1 Other segment expenses include expenses not captured in the primary categories above, such as stock-based compensation, depreciation and amortization, interest income and interest expense.
|